Lipoprotein(a) in health and disease

Critical Reviews in Clinical Laboratory Sciences

Volumn 33, Issue 6, 1996, Pages 495-543

  Kronenberg, Florian ^a   Steinmetz, Armin ^b   Kostner, Gerhard M ^c   Dieplinger, Hans ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Apo(a) phenotypes; Apolipoprotein; Atherosclerosis; Epidemiology; Renal disease; Risk factor

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; DISULFIDE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLASMINOGEN;

ATHEROSCLEROSIS; CHROMOSOME 6Q; ENZYME DEFICIENCY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC RISK; HEALTH; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; MOLECULAR WEIGHT; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PERIPHERAL VASCULAR DISEASE; PHENOTYPE; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; RISK FACTOR; SEQUENCE HOMOLOGY; STANDARDIZATION; STROKE; VASCULAR DISEASE;

EID: 0030470008     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408369609080056     Document Type: Review

References (238)

1. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-82.
2. McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature (London) 1987; 300: 132-7.
3. Murray JC, Buetow KH, Donovan M, et al. Linkage disequilibrium of plasminogen polymorphisms and assignment of the gene to human chromosome 6q26-6q27. Am J Hum Genet 1987; 40: 338-50.
4. Kratzin H, Armstrong VW, Niehaus M, et al. Structural relationship of an apolipoprotein(a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydraterich regions. Biol Chem Hoppe Seyler 1987; 368: 1533-44.
5. Lawn RM, Boonmark NW, Schwartz K, et al. The recurring evolution of lipoprotein(a) - Insights from cloning of hedgehog apolipoprotein(a). J Biol Chem 1995; 270: 24004-9.
6. Lackner C, Cohen JC Hobbs HH: Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993; 2: 933-40.
7. Van der Hoek YY, Wittekoek ME, Beisiegel U, et al. The apolipoprotein(a) kringle IV repeats that differ from the major repeat kringle are present in variably sized isoforms. Hum Mol Genet 1993; 2: 361-6.
8. Scanu AM. Identification of mutations in human apolipoprotein(a) kringle 4-37 from the study of the DNA of peripheral blood lymphocytes: relevance to the role of lipoprotein(a) in atherothrombosis. Am J Cardiol 1995; 75: 58B-61B.
9. Klezovitch O, Scanu AM. Lys and fibrinogen binding of wild-type (Trp72) and mutant (Arg72) human apo(a) kringle IV-10 expressed in E. coli and CHO cells. Arteriosder Thromb Vasc Biol 1996; 16: 392-8.
10. Gaw A, Hobbs HH. Molecular genetics of lipoprotein(a): new pieces to the puzzle. Curr Opin Lipidol 1994; 5: 159-65.
11. Kraft HG, Menzel HJ, Hoppichler F, et al. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989; 83: 137-42.
12. Koschinsky ML, Côté GP, Gabel B, et al. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 1993; 268: 19819-25.
13. Brunner C, Kraft HG, Utermann G, et al. Cys(4057) of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sc USA 1993; 90: 11643-7.
14. Frank S, Krasznai K, Durovic S, et al. High-level expression of various apolipoprotein(a) isoforms by "transferrinfection": the role of kringle IV sequences in the extracellular association with low- density lipoprotein. Biochemistry 1994; 33: 12329-39.
15. McCormick SPA, No JK, Taylor S, et al. Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc Natl Acad Sci USA 1995; 92: 10147-51.
16. White AL, Lanford RE. Biosynthesis and metabolism of lipoprotein(a). Curr Opin Lipidol 1995; 6: 75-80.
17. White AL, Lanford RE: Apo(a) folding in the endoplasmatic reticulum. Circulation 1995; 92(Suppl. I): I-2(Abstr).
18. Edelstein C, Mandala M, Pfaffinger D, et al. Determinants of lipoprotein(a) assembly: A study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry 1995; 34: 16483-92.
19. Slunga L, Johnson O Dahlén GH. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol 1992; 43: 369-73.
20. O'Connor P, Cooke T Feely J. Effects of HMG Co-A reductase inhibitors on lipids and lipoprotein(a) in hypercholesterolaemia. Drug Invest 1992; 4: 227-31.
21. Rader DJ, Mann WA, Cain W, et al. The low-density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95: 1403-8.
22. Krempler F, Kostner GM, Bolzano K, et al. Turnover of lipoprotein(a) in man. J Clin Invest 1980; 65: 1483-90.
23. Rader DJ, Cain W, Zech LA, et al. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993; 91: 443-7.
24. Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458-65.
25. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904-10.
26. Utermann G, Hoppichler F, Dieplinger H, et al. Defects in the low-density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 1989; 86: 4171-4.
27. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991; 86: 607-14.
28. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: The Framingham Offspring Study. Circulation 1993; 87: 1135-41.
29. Farish E, Rolton HA, Barnes JF, et al. Lipoprotein(a) and postmenopausal oestrogen. Acta Endocrinol (Copenhagen) 1993; 129: 225-8.
30. Kamboh MI, Ferrell RE Kottke BA. Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet 1991; 49: 1063-74.
31. Marcovina SM, Zhang ZH, Gaur VP, et al. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun 1993; 191: 1192-6.
32. Utermann G, Haibach C, Trommsdorff M, et al. Genetic architecture of the atherogenic lipoprotein(a). Ann NY Acad Sci 1995; 748: 301-12.
33. Lackner C, Boerwinkle E, Leffert CC, et al. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991; 87: 2153-61.
34. Kraft HG, Köchl S, Menzel HJ, et al. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 1992; 90: 220-30.
35. Kraft HG, Lingenhel A, Bader G, et al. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 1996; 125: 53-61.
36. Boerwinkle E, Menzel HJ, Kraft HG, et al. Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 1989; 82: 73-8.
37. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52-60.
38. Austin MA, Sandholzer C, Selby JV, et al. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet 1992; 51: 829-40.
39. Mooser V, Mancini FP, Bopp S, et al. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet 1995; 4: 173-81.
40. Trommsdorff M, Köchl S, Lingenhel A, et al. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 1995; 96: 150-7.
41. Mancini FP, Mooser V, Guerra R, et al. Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum Mol Genet 1995; 4: 1535-42.
42. Zysow BR, Lindahl GE, Wade DP, et al. C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb 1995; 15: 58-64.
43. Howard GC, Pizzo SV. Lipoprotein(a) and its role in atherothrombotic disease. Lab Invest 1993; 69: 373-86.
44. Harpel PC, Hermann A, Zhang XX, et al. Lipoprotein(a), plasmin modulation, and atherogenesis. Thromb Haemost 1995; 74: 382-6.
45. Harpel PC, Gordon BR Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86: 3847-51.
46. Miles LA, Fless GM, Levin EG, et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature (London) 1989; 339: 301-3.
47. Hajjar KA, Gavish D, Breslow JL, et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature (London) 1989; 339: 303-5.
48. Harpel PC, Chang VT Borth W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-7.
49. Edelberg JM, Gonzalez-Gronow M Pizzo SV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989; 28: 2370-4.
50. Karádi I, Kostner GM, Gries A, et al. Lipoprotein(a) and plasminogen are immunochemically related. Biochim Biophys Acta 1988; 960: 91-7.
51. März W, Trommlitz M, Scharrer I, et al. Apolipoprotein(a) concentrations are not related to the risk of venous thrombosis. Blood Coag Fibrinol 1991; 2: 595-9.
52. Donders SHJ, Lustermans FAT Van Wersch JWJ. On lipoprotein(a) and the coagulation/fibrinolysis balance in the acute phase of deep venous thrombosis. Fibrinolysis 1993; 7: 83-6.
53. Palabrica TM, Liu AC, Aronovitz MJ, et al. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Medicine 1995; 1: 256-9.
54. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655-8.
55. Grainger DJ, Kemp PR, Liu AC, et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature (London) 1994; 370: 460-2.
56. Albers JJ, Marcovina SM. Lipoprotein(a) quantification: comparison of methods and strategies for standardization. Curr Opin Lipidol 1994; 5: 417-21.
57. Kostner GM. Standardization of Lp(a) assays. Clin Chim Acta 1992; 211: 191-4.
58. Fless GM, Snyder ML, Furbee JW, Jr., et al. Subunit composition of lipoprotein(a) protein. Biochemistry 1994; 33: 13492-501.
59. Seman LJ, Jenner JL, McNamara JR, et al. Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction. Clin Chem 1994; 40: 400-3.
60. Nauck M, Winkler K, Wittmann C, et al. Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol. Clin Chem 1995; 41: 731-8.
61. Tiran A, Tiran B, Hojas S, et al. Immunoquantification of lipoprotein(a): comparison of nephelometry with electroimmunodiffusion. J Clin Lab Anal 1993; 7: 256-62.
62. +) lipoprotein. J Lipid Res 1985; 26: 267-9.
63. Kronenberg F, Lobentanz E-M, König P, et al. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol, and triglycerides. J Lipid Res 1994; 35: 1318-28.
64. Taddei-Peters WC, Butman BT, Jones GR, et al. Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay. Clin Chem 1993; 39: 1382-9.
65. Steyrer E, Durovic S, Frank S, et al. The role of lecithin:cholesterol acyltransferase for lipoprotein(a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 1994; 94: 2330-40.
66. Gries A, Nimpf J, Nimpf M, et al. Free and Apo B-associated Lp(a)-specific protein in human serum. Clin Chim Acta 1987; 164: 93-100.
67. Albers JJ, Marcovina SM. Standardization of Lp(a) measurements. Chem Phys Lipids 1994; 67-8: 257-63.
68. Labeur C, Rosseneu M Henderson O: International Lp(a) standardization. Chem Phys Lipids 1994; 67-8: 265-70.
69. Tate J. Lipoprotein(a) standardization within Australia and New Zealand. Clin Biochem Revs 1994; 15: 74-81.
70. Campbell B, Tate J, Lepre F, et al. Lipoprotein(a): biology, clinical utility and measurement. Clin Biochem Revs 1992; 13: 55-9.
71. Marcovina SM, Albers JJ, Gabel B, et al. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995; 41: 246-55.
72. Marcovina SM, Morrisett JD. Structure and metabolism of lipoprotein(a). Curr Opin Lipidol 1995; 6: 136-45.
73. Kronenberg F, König P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-20.
74. Rosengren A, Wilhelmsen L, Eriksson E, et al. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle-aged men. Br Med J 1990; 301: 1248-51.
75. Sigurdsson G, Baldursdottir A, Sigvaldason H, et al. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992; 69: 1251-4.
76. Cressman MD, Heyka RJ, Paganini EP, et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475-82.
77. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994; 343: 75-9.
78. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men - The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994; 271: 999-1003.
79. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-53.
80. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 1994; 90: 1688-95.
81. Cantin B, Moorjani S, Després J-P, et al. Lp(a) in ischemic heart disease. The Québec Cardiovascular Study. J Am Coll Cardiol 1994; 23: 482A(Abstr)
82. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.
83. Ridker PM, Hennekens CH Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-9.
84. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relationship of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
85. Dahlen G. The pre-beta1 lipoprotein phenomenon in relation to serum cholesterol and triglyceride levels, the Lp(a) lipoprotein and coronary heart disease. Acta Med Scand 1974; Suppl. 570: 1-45.
86. Kostner GM, Avogaro P, Cazzolato G, et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38: 51-61.
87. Sandkamp M, Funke H, Schulte H, et al. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990; 36: 20-3.
88. Parra HJ, Arveiler D, Evans AE, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: The ECTIM study. Arteriosder Thromb 1992; 12: 701-7.
89. Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-65.
90. Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis 1986; 62: 249-57.
91. Genest J, Jr., Jenner JL, McNamara JR, et al. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 1991; 67: 1039-45.
92. Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb 1992; 12: 1214-26.
93. Seed M, Hoppichler F, Reaveley D, et al. Relationship of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494-9.
94. Wiklund O, Angelin B, Olofsson S-O, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990; 335: 1360-3.
95. Craig WY, Poulin SE, Forster NR, et al. Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme-linked immunosorbent assay kits. Clin Chem 1992; 38: 550-3.
96. Desmarais RL, Sarembock IJ, Ayers CR, et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91: 1403-9.
97. Hearn JA, Donohue BC, Ba'albaki H, et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69: 736-9.
98. Terres W, Tatsis E, Pfalzer B, et al. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995; 91: 948-50.
99. Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995; 76: 928-32.
100. Sandholzer C, Boerwinkle E, Sana N, et al: Apolipoprotein(a) phenotypes, Lp(a) concentration, and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992; 89: 1040-6.
101. Költringer P, Jürgens G. A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 1985; 58: 187-98.
102. Asplund K, Olsson T, Viitanen M, et al. Lp(a) lipoprotein in patients with acute stroke. Cerebrovasc Dis 1991; 1: 90-6.
103. Pedro-Botet J, Sentí M, Nogués X, et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke: role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 1992; 23: 1556-62.
104. Jovicic A, Ivanisevic V Ivanovic I. Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 1993; 98: 59-65.
105. Nagayama M, Shinohara Y Nagayama T. Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke 1994; 25: 74-8.
106. Shintani S, Kikuchi S, Hamaguchi H, et al. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke 1993; 24: 965-9.
107. Ridker PM, Stampfer MJ Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995; 273: 1269-73.
108. Kronenberg F, Kathrein H, König P, et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arteriosder Thromb 1994; 14: 1405-11.
109. Brown SA, Morrisett JD, Boerwinkle E, et al. The relationship of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study, Arteriosder Thromb 1993; 13: 1558-66.
110. Tatò F, Keller C, Schuster H, et al. Relationship of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis 1993; 101: 69-77.
111. Cambillau M, Simon A, Amar J, et al. Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. Arteriosder Thromb 1992; 12: 1346-52.
112. Wendelhag I, Wiklund O Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia: ultrasonographic assessment of intima-media thickness and plaque occurrence. Arteriosder Thromb 1993; 13: 1404-11.
113. Schreiner PJ, Morrisett JD, Sharrett AR, et al. Lipoprotein[a] as a risk factor for preclinical atherosclerosis. Arteriosder Thromb 1993; 13: 826-33.
114. Rankinen T, Väisänen S, Mercuri M, et al. Apolipoprotein(a), fibrinopeptide A and carotid atherosclerosis in middle-aged men. Thromb Haemost 1994; 72: 563-6.
115. Willeit J, Kiechl S, Santer P, et al. Lipoprotein(a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: The Bruneck Study. Stroke 1995; 26: 1582-7.
116. Mölgaard J, Klausen IC, Lassvik C, et al. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arteriosder Thromb 1992; 12: 895-901.
117. Tyrrell J, Cooke T, Reilly M, et al. Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med 1992; 232: 349-52.
118. Valentine RJ, Grayburn PA, Vega GL, et al. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994; 154: 801-6.
119. Cantin B, Moorjani S, Dagenais GR, et al. Lipoprotein(a) distribution in a French Canadian population and its relationship to intermittent claudication (The Québec Cardiovascular Study). Am J Cardiol 1995; 75: 1224-8.
120. Callow MJ, Verstuyft J, Tangirala R, et al. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 1995; 96: 1639-46.
121. Mancini FP, Newland DL, Mooser V, et al. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arteriostier Thromb Vasc Biol 1995; 15: 1911-6.
122. Lawn RM, Wade DP, Hammer RE, et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature (London) 1992; 360: 670-2.
123. Kronenberg F, Utermann G Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27: 1-25.
124. Wanner C, Bartens W: Lipoprotein(a) in renal patients: is it a key factor in the high cardiovascular mortality? Nephrol Dial Transplant 1994; 9: 1066-8.
125. Kronenberg F. Lipoprotein(a) in renal disease: what we have, what we need, what we can forget. Nephrol Dial Transplant 1995; 10: 766-9.
126. Karádi I, Romics L, Pálos G, et al. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989; 35: 2121-3.
127. Faucher C, Doucet C, Baumelou A, et al. Elevated lipoprotein (a) levels in primary nephrotic syndrome. Am J Kidney Dis 1993; 22: 808-13.
128. Takegoshi T, Kitoh C, Haba T, et al. A study of the clinical significance of lipoprotein(a) in nephrotic syndrome. Jpn J Med 1991; 30: 21-5.
129. Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993; 119: 263-9.
130. Stenvinkel P, Berglund L, Heimbürger O, et al. Lipoprotein(a) in nephrotic syndrome. Kidney Int 1993; 44: 1116-23.
131. Joven J, Simó JM, Vilella E, et al. Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relationship to remission of proteinuria. Clin Chem 1995; 41: 908-13.
132. Gansevoort RT, Heeg JE, Dikkeschei FD, et al. Symptomatic antiproteinuric treatment decreases serum lipoprotein(a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994; 9: 244-50.
133. Dieplinger H, Lackner C, Kronenberg F. et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993; 91: 397-401.
134. Appel GB, Blum CB, Chien S, et al. The hyperlipidemia of nephrotic syndrome: relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med 1985; 312: 1544-8.
135. Hirata K, Kikuchi S, Saku K, et al. Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int 1993; 44: 1062-70.
136. Auguet T, Sentí M, Rubies-Prat J, et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving hemodialysis: influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 1993; 8: 1099-103.
137. Webb AT, Reaveley DA, O'Donnell M, et al. Lipoprotein(a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8: 609-13.
138. Barbagallo CM, Averna MR, Sparacino V, et al. Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron 1993; 64: 560-4.
139. Fiorini F, Masturzo P, Mij M, et al. Lipoprotein(a) levels in hemodialysis patients: relationship to glucose intolerance and hemodialysis duration. Nephron 1995; 70: 500-1.
140. Murphy BG, McNamec PT. Apolipoprotein(a) concentration decreases following renal transplantation. Nephrol Dial Transplant 1992; 7: 174-5.
141. Gault MH, Longerich LL, Purchase L, et al. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 1995; 70: 155-70.
142. Webb A, Misra M, Reaveley D, et al. Effect of change of renal replacement therapy on plasma lipoprotein(a) concentration. Atherosclerosis 1994; 109: 277(Abstr)
143. Black IW, Wilcken DEL. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 1992; 38: 353-7.
144. Kronenberg F, König P, Lhotta K, et al. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993; 341: 765
145. Yang CW, Kim YS, Kim SY, et al. Serum levels of lipoprotein(a) after renal transplantation: short-term follow-up [lett]. Nephron 1994; 67: 364
146. Segarra A, Chacón P, Martin M, et al. Serum lipoprotein (a) levels in patients with chronic renal failure - evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study. Nephron 1995; 69: 9-13.
147. Azrolan N, Brown CD, Thomas L, et al. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients. Arterioscler Thromb 1994; 14: 1393-8.
148. Kronenberg F, König P, Lhotta K, et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 1994; 14: 1399-404.
149. Murphy BG, Yong A, Brown JH, et al. Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation. Atherosclerosis 1995; 116: 241-5.
150. Segarra A, Chacón P, Vilardell M, et al. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993; 341: 766.
151. Moore R, Thomas D, Morgan E, et al. Abnormal lipid and lipoprotein profiles following renal transplantation. Transplant Proc 1993; 25: 1060-1.
152. Webb AT, Reaveley DA, O'Donnell M, et al. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?. Lancet 1993; 341: 268-70.
153. Hunt BJ, Parratt R, Rose M, et al. Does cyclosporin affect lipoprotein(a) concentrations? Lancet 1994; 343: 119-20.
154. Sturrock NDC, Lang CC, MacFarlane LJ, et al. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J Hypertens 1995; 13: 667-73.
155. Edwards BD, Bhatnagar D, Mackness MI, et al. Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. Q J Med 1995; 88: 109-13.
156. Wanner C, Bartens W, Walz G, et al. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant 1995; 10: 75-81.
157. Webb AT, Reaveley DA, O'Donnell M, et al. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1995; 10: 354-7.
158. Oida K, Takai H, Maeda H, et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992; 38: 2244-8.
159. Mooser V, Seabra MC, Abedin M, et al. Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). J Clin Invest 1996; 97: 858-64.
160. Haffner SM, Morales PA, Stern MP, et al. Lp(a) concentrations in NIDDM. Diabetes 1992; 41: 1267-72.
161. Velho G, Erlich D, Turpin E, et al. Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care 1993; 16: 742-7.
162. Imperatore G, Rivellese A, Galasso R, et al. Lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus and borderline hyperglycemia: a population-based study. Metabolism 1995; 44: 1293-7.
163. Heller FR, Jamart J, Honore P, et al. Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care 1993; 16: 819-23.
164. Császár A, Dieplinger H, Sandholzer C, et al. Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia 1993; 36: 47-51.
165. O'Brien T, Nguyen TT, Harrison JM, et al. Lipids and Lp(a) lipoprotein levels and coronary artery disease in subjects with non-insulin-dependent diabetes mellitus. Mayo Clin Proc 1994; 69: 430-5.
166. Chang C-J, Kao J-T, Wu T-J, et al. Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients: relationship to metabolic control. Diabetes Care 1995; 18: 1191-4.
167. Klausen IC, Berg Schmidt E, Lervang HH, et al. Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest 1992; 22: 538-41.
168. Couper JJ, Bates DJ, Cocciolone R, et al. Association of lipoprotein(a) with puberty in IDDM. Diabetes Care 1993; 16: 869-73.
169. Salzer B, Stavljenic A, Jürgens G, et al. Polymorphism of apolipoprotein E, lipoprotein(a), and other lipoproteins in children with type I diabetes. Clin Chem 1993; 39: 1427-32.
170. Oscarsson J, Ottosson M, Wiklund O, et al. Low-dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low-density lipoprotein cholesterol concentrations in middle-aged men. Clin Endocrinol 1994; 41: 109-16.
171. James RW, Boemi M, Sirolla C, et al. Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia 1995; 38: 711-4.
172. Dubrey SW, Reaveley DR, Seed M, et al. Risk factors for cardiovascular disease in IDDM - a study of identical twins. Diabetes 1994; 43: 831-5.
173. Purnell JQ, Marcovina SM, Hokanson JE, et al: Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM - results from follow-up in the diabetes control and complications trial. Diabetes 1995; 44: 1218-26.
174. Bruckert E, Davidoff P, Grimaldi A, et al. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 1990; 263: 35-6.
175. Haffner SM, Tuttle KR Rainwater DL. Decrease of lipoprotein(a) with
176. Makino K, Furbee JW, Jr., Scanu AM, et al. Effect of glycation on the properties of lipoprotein(a). Arterioscler Thromb 1995; 15: 385-91.
177. Doucet C, Huby T, Ruiz J, et al. Nonenzymatic glycation of lipoprotein(a) in vitro and in vivo. Atherosclerosis 1995; 118: 135-43.
178. Jenkins AJ, Steele JS, Janus ED, et al. Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 1991; 40: 787-90.
179. Kapelrud H, Bangstad H-J, Dahl-Jorgensen K, et al. Serum Lp(a) lipoprotein concentrations in insulin-dependent diabetic patients with microalbuminuria.. Br Med J 1991; 303: 675-8.
180. Gall M-A, Rossing P, Hommel E, et al. Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. Scand J Clin Lab Invest 1992; 52: 513-21.
181. Schnack C, Pietschmann P, Knobl P, et al. Apolipoprotein (a) levels and atherogenic lipid fractions in relation to the degree of urinary albumin excretion in type 2 diabetes mellitus. Nephron 1994; 66: 273-7.
182. Girelli A, Cimino A, Rocca L, et al. Serum lipoprotein (a) is not increased in NIDDM patients with microalbuminuria. Diabetes Care 1994; 17: 456-7.
183. Gruden G, Veglio M, Cavallo-Perin P, et al. Lipoprotein(a) in non-insulin-dependent diabetic patients with normo- and microalbuminuria. Horm Metab Res 1994; 26: 489-90.
184. Zambon S, Baldo-Enzi G, Baiocchi M, et al. Lipoprotein(a) levels in type II diabetic patients are not influenced by metabolic control or by microalbuminuria. Diabetes Care 1994; 17: 1548-9.
185. Jenkins AJ, Steele JS, Janus ED, et al. Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1992; 35: 1055-9.
186. Heesen BJ, Wolffenbuttel BHR, Leurs PB, et al. Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. Eur J Clin Invest 1993; 23: 580-4.
187. Hiraga T, Kobayashi T, Okubo M, et al. Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 1995; 18: 241-4.
188. Haffner SM, Moss SE, Klein BEK, et al. Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: The Wisconsin Epidemiologie Study of Diabetic Retinopathy. Metabolism 1992; 41: 194-7.
189. Maser RE, Usher D, Becker DJ, et al. Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh epidemiology of diabetes complications study cohort. Diabetes Care 1993; 16: 755-8.
190. Hughes JK, Mendelsohn D. Serum lipoprotein (a) levels in "normal" individuals, those with familial hypercholesterolaemia, and those with coronary artery disease. S Afr Med J 1990; 78: 567-70.
191. Friedlander Y, Leitersdorf E. Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemia. Genet Epidemiol 1995; 12: 129-43.
192. Bowden J-F, Pritchard PH, Hill JS, et al. Lp(a) concentration and apo(a) isoform size: relationship to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1561-8.
193. MBewu AD, Bhatnagar D, Durrington PN, et al. Serum lipoprotein(a) in patients heterozygous familial hypercholesterolaemia, their relatives, and unrelated control populations. Arteriosclerosis 1991; 11: 940-6.
194. Knight BL, Perombelon YFN, Soutar AK, et al. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis 1991; 87: 227-37.
195. Kostner GM, Gavish D, Leopold B, et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313-9.
196. Menzel H-J, Dieplinger H, Lackner C, et al. Abetalipoproteinemia with an apoB-100-lipoprotein(a) glycoprotein complex in plasma: indication for an assembly defect. J Biol Chem 1990; 265: 981-6.
197. 100. Atherosclerosis 1992; 92: 203-12.
198. Hansen PS, Meinertz H, Jensen HK, et al. Characteristics of 46 heterozygous carriers and 57 unaffected relatives in five Danish families with familial defective apolipoprotein B-100. Arterioscler Thromb 1994; 14: 207-13.
199. 3500 → Gln). A study of the assembly of recombinant apolipoprotein (a) with mutant low-density lipoproteins. J Biol Chem 1994; 269: 30320-5.
200. Sandholzer C, Feussner G, Brunzell J, et al. Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency with type III hyperlipoproteinemia: no evidence for a triglyceride-rich precursor of lipoprotein(a). J Clin Invest 1992; 90: 1958-65.
201. De Bruin TWA, Van Barlingen H, Van Linde-Sibenius Trip M, et al. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Metab 1993; 76: 121-6.
202. Kung AWC, Pang RWC, Lauder I, et al. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Clin Chem 1995; 41: 226-31.
203. Hoppichler F, Sandholzer C, Moncayo R, et al. Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels. Atherosclerosis 1995; 115: 65-71.
204. Engler H, Riesen WF. Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem 1993; 39: 2466-9.
205. Kurbaan AS, Barbir M Ilsley GDJ: Normalization of lipoprotein (a) following successful treatment of hypothyroidism. Q.J.Med. 1995; 88: 221-3.
206. Yamamoto K, Ozaki I, Fukushima N, et al. Serum lipoprotein(a) levels before and after subtotal thyroidectomy in subjects with hyperthyroidism. Metabolism 1995; 44: 4-7.
207. Klausen IC, Hegedüs L, Hansen PS, et al. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism. Clin Invest 1995; 73: 41-6.
208. Feely J, Barry M, Keeling PWN, et al. Lipoprotein(a) in cirrhosis. Br Med J 1992; 304: 545-6.
209. Van Wersch JWJ. The behavior of lipoprotein(a) in patients with various diseases. Scand J Clin Lab Invest 1994; 54: 559-62.
210. Selvais P, Henrion J, Schapira M, et al. La lipoprotéine(a) dans les hépatopathies. Corrélation entre sa diminution et l'état fonctionnel du foie. Presse Med 1995; 24: 382-6.
211. Gregory WL, Game FL, Farrer M, et al. Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 1994; 105: 43-50.
212. Marth E, Cazzolato G, Bon B, et al. Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann Nutr Metab 1982; 26: 56-62.
213. Kervinen K, Savolainen MJ Kesäniemi YA: A rapid increase in lipoprotein (a) levels after ethanol withdrawal in alcoholic men. Life Sci 1991; 48: 2183-8.
214. Maeda S, Abe A, Seishima M, et al. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145-50.
215. Slunga L, Johnson O, Dahlén GH, et al. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 1992; 52: 95-101.
216. Frazer KA, Narla G, Zhang JL, et al. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet 1995; 9: 424-31.
217. Borba EF, Santos RD, Bonfa E, et al. Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994; 21: 220-3.
218. Matsuda J, Gotoh M, Gohchi K, et al. Serum lipoprotein(a) level is increased in patients with systemic lupus erythematosus irrespective of positivity of antiphospholipid antibodies. Thromb Res 1994; 73: 83-4.
219. Rantapää-Dahlqvist S, Wållberg-Jonsson S Dahlén G: Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50: 366-8.
220. Takahashi S, Yamamoto T, Moriwaki Y, et al. Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. Ann Rheum Dis 1995; 54: 90-3.
221. Wright LC, Sullivan DR, Muller M, et al. Elevated apolipoprotein(a) levels in cancer patients. Int J Cancer 1989; 43: 241-4.
222. Nakahama H, Nakanishi T, Uyama O, et al. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis. Ren Fail 1993; 15: 189-93.
223. Carlson LA, Hamsten A Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271-6.
224. Albers JJ, Taggart HM, Appelbaum-Bowden D, et al. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanazolol. Biochim Biophys Acta 1984; 795: 293-6.
225. Crook D, Sidhu M, Seed M, et al. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992; 92: 41-7.
226. Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86: 1534-9.
227. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994; 14: 1586-93.
228. Haenggi W, Riesen W Birkhaeuser MH. Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein(a). Eur J Clin Chem Clin Biochem 1993; 31: 645-50.
229. Farish E, Barnes JF, Rolton HA, et al. Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1994; 20: 215-9.
230. Schenck I, Keller C, Hailer S, et al. Reduction of Lp(a) by different methods of plasma exchange. Klin Wochenschr 1988; 66: 1197-201.
231. Bosch T, Thiery J, Gurland HJ, et al. Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and haemodialysis in patients with hypercholesterolaemia and end-stage renal failure. Nephrol Dial Transplant 1993; 8: 1350-8.
232. Frank S, Durovic S, Kostner K, et al. Inhibitors for the in vitro assembly of Lp(a). Arterioscler Thromb Vasc Biol 1995; 15: 1774-80.
233. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, et al. eds. The metabolic and molecular bases of inherited disease. Pp 1887-912. New York: McGraw-Hill, 1995.
234. Couderc R. Member of the Société Française de Biologie Clinique, Service Biochemie, Hôpital Tenon, Paris. Personal communication.
235. Sakurabayashi I. department of Clinical Laboratory, Jichi Medical School, Tokyo. Personal communication.
236. Kronenberg F, et al. Unpublished data.
237. Assmann G, Schulte H von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middleaged men. Am J Cardiol 1996; 77: 1179-84.
238. Kronenberg F, Trenkwalder E Dieplinger H Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time: why epidemiological studies might fail. Arterioscler Thromb Vasc Biol 1996; (in press).